Skip to main navigation
×
CLOSE
Home
Development Programs
VX15 Immuno-Oncology
VX15 Neurology
VX18 Neurology
VX15 Autoimmune
NKT Vaccine
NKT Vaccine
ActivMAb
®
Vaccinia Display
Capabilities
Optimization
Target Identification
Publications
News & Publications
News
Publications
Careers
Corporate
Management
Partners
Contact
Investors
Main navigation
Investor Overview
News Releases
Events
Presentations
Stock Information
Stock Quote & Chart
Historical Price Lookup
Corporate Governance
Documents & Charters
Management
Board of Directors
Committee Composition
Financial Information
SEC Filings
Investor Services
Information Request
IR Contacts
E-mail Alerts
Events
Presentations
Home
About
Corporate Overview
Management
Partners
Pipeline
Pepinemab
Neurology
Pepinemab
Immuno-Oncology
Research & Development Programs
Clinical Trials
Patients
Physicians & Researchers
News & Publications
News
Publications
Investors
Main navigation
Investor Overview
News Releases
Events
Presentations
Stock Information
Stock Quote & Chart
Historical Price Lookup
Corporate Governance
Documents & Charters
Management
Board of Directors
Committee Composition
Financial Information
SEC Filings
Investor Services
Information Request
IR Contacts
E-mail Alerts
Events
Presentations
Careers
Contact Us
ActivMAb
®
Vaccinia
Antibody Discovery
Antigen Virus
Protein Optimization
Antigen Discovery
Antibody Optimization
ActivMAb
®
Contact
Science in the service of medicine
About
Corporate Overview
Management
Partners
Pipeline
Pepinemab Neurology
Pepinemab Immuno-Oncology
Research & Development Programs
Clinical Trials
Patients
Physicians & Researchers
News & Publications
News
Publications
Investors
Main navigation
Investor Overview
News Releases
Events
Presentations
Stock Information
Stock Quote & Chart
Historical Price Lookup
Corporate Governance
Documents & Charters
Management
Board of Directors
Committee Composition
Financial Information
SEC Filings
Investor Services
Information Request
IR Contacts
E-mail Alerts
Events
Presentations
Careers
Contact Us
ActivMAb
®
Vaccinia
Antibody Discovery
Antigen Virus
Protein Optimization
Antigen Discovery
Antibody Optimization
Contact Us
Investors
Investor Overview
News Releases
Events
Presentations
Stock Information
Corporate Governance
Financial Information
Investor Services
Shareholder Tools
Print Page
RSS Feeds
E-mail Alerts
IR Contacts
LinkedIn
Twitter
Filter by content type
(-)
Event
(9)
Filter by form group
Filter by year
(-)
2019
(9)
Search
Event
Vaccinex, Inc. at the PEPTALK: Advancing CNS Biotherapeutics and Crossing the Blood-Brain Barrier
Event
Q4 2018 Vaccinex, Inc. Earnings Release
Event
Vaccinex, Inc. at the Oppenheimer & Co.’s 29th Annual Healthcare Conference
Event
AACR 2019 Meeting: Vaccinex, Inc. - Integrated biomarker trials of VX15/2503 (pepinemab) in combination with checkpoint inhibitors in window of opportunity studies in solid tumors
Event
AACR 2019 Meeting: Vaccinex, Inc. - Altered myeloid and lymphoid composition of tumor microenvironment following anti-SEMA4D and immune checkpoint combination therapies
Event
ASCO Annual Meeting: Vaccinex, Inc. - Interim results from CLASSICAL-Lung, a Phase Ib/II study of VX15/2503 (pepinemab) in combination with avelumab in advanced NSCLC
Event
ASCO Annual Meeting: Preliminary Results From CLASSICAL-Lung, a Phase 1b/2 Study of Pepinemab (VX15/2503) in Combination with Avelumab in Advanced Non-Small Cell Lung Cancer (NSCLC)
Event
ASCO Annual Meeting: Pilot Integrated Biomarker Study of VX15/2503 in Combination with Ipilimumab and/or Nivolumab in Patients with Resectable Metastatic Melanoma
Event
Vaccinex to Present at the Ladenburg Thalmann 2019 Healthcare Conference